Business
ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025
ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with lenvatinib for patients with advanced hepatocellular carcinoma (HCC). The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.
About this update from Immuneoncia Therapeutics Inc.
[{"type":"text","content":"CHICAGO, June 2, 2025 /PRNewswire/ -- ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with lenvatinib for patients with advanced hepatocellular carcinoma (HCC). The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.","length":421,"tagName":"p"},{"type":"image","alt":"ImmuneOncia","displaySize":"","headline":null,"caption":"ImmuneOncia","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/37e1e5ff99a71c5c8e78ebfc557792c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mUoRv5d5e_U3gDEPaXZRXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/37e1e5ff99a71c5c8e78ebfc557792c6","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2700898/ImmuneOncia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study, part of the dose-expansion phase, evaluated the safety and early efficacy of the combination therapy. IMC-002 demonstrated a favorable safety profile with no reported cases of neutropenia or thrombocytopenia. Mild anemia was observed in 2 of 13 patients (15%), and 96% of adverse events were Grade 1–2, occurring primarily in the first treatment cycle.","length":363,"tagName":"p"},{"type":"text","content":"Among 10 patients evaluable for efficacy, 3 (30%) showed a partial response (PR), while the disease control rate (DCR) reached 80%. The median progression-free survival (PFS) was 8.3 months. Notably, two patients have remained on treatment for over one year, indicating the potential for sustained therapeutic benefit.","length":318,"tagName":"p"},{"type":"text","content":"AI-powered digital pathology analysis showed a 60% objective response rate (ORR) in patients with high CD47 expression on tumor cell membranes, whereas no response was observed in those with low expression - a statistically significant difference (p=0.018). These findings support CD47 expression as a predictive biomarker for response.","length":336,"tagName":"p"},{"type":"text","content":"Professor Jeong-Yong Hong of Samsung Medical Center commented, "The IMC-002 and lenvatinib combinat...